scholarly journals Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses

2012 ◽  
Vol 28 (6) ◽  
pp. 963-968 ◽  
Author(s):  
Sebastiano Mercadante ◽  
Antonio Gatti ◽  
Giampiero Porzio ◽  
Claudio Lo Presti ◽  
Federica Aielli ◽  
...  
2014 ◽  
Vol 19 (4) ◽  
pp. 528-537 ◽  
Author(s):  
U.R. Kleeberg ◽  
A. Davies ◽  
J. Jarosz ◽  
S. Mercadante ◽  
P. Poulain ◽  
...  

Pain Practice ◽  
2010 ◽  
Vol 11 (2) ◽  
pp. 185-190 ◽  
Author(s):  
Ulrich R. Kleeberg ◽  
Marilène Filbet ◽  
Giovambattista Zeppetella

2015 ◽  
Vol 23 (7) ◽  
pp. 2135-2143 ◽  
Author(s):  
Andrew Davies ◽  
Ulrich R. Kleeberg ◽  
Jerzy Jarosz ◽  
Sebastiano Mercadante ◽  
Philippe Poulain ◽  
...  

2020 ◽  
pp. 107815522098342
Author(s):  
Jacopo Giuliani ◽  
Francesco Fiorica ◽  
Alfredo Sacchetto ◽  
Gianfranco Franceschini ◽  
Ferdinando Vaccari ◽  
...  

The aim of this paper was to assess the drug costs of the different biotechnologies (intranasal fentanyl spray (INFS), oral transmucosal fentanyl citrate (OTFC) and fentanyl buccal tablet (FBT)) in the treatment of breakthrough cancer pain (BTCP). We have calculated the mean drug costs (expressed in euros (€)) for patients treated for BTCP. INFS resulted the less expensive towards OTFC and FBT, with 697 440 €versus (vs.) 809 552 €vs. 779 662 €every 100 patients treated for BTCP, respectively. In conclusion, combining drug costs of different biotechnologies (INFS, OTFC and FBT) with the measure of efficacy represented by the reduction of BTCP avoided (incremental cost-effectiveness ratio, ICER), INFS resulted in better cost-effectiveness.


Sign in / Sign up

Export Citation Format

Share Document